WEBULL
News
ABCL
3.220
+1.90%
0.060
Weekly Report: what happened at ABCL last week (0202-0206)?
Weekly Report · 1d ago
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions?
Simply Wall St · 4d ago
OpenAI considers backing AI-led drug discovery firms: report
Seeking Alpha · 6d ago
Weekly Report: what happened at ABCL last week (0126-0130)?
Weekly Report · 02/02 09:09
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
Simply Wall St · 01/30 08:38
Weekly Report: what happened at ABCL last week (0119-0123)?
Weekly Report · 01/26 09:09
Advancing Non-Hormonal Menopause Drug Into Phase 2 Could Be A Game Changer For AbCellera (ABCL)
Simply Wall St · 01/24 09:30
Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Dow Jones · 01/23 00:10
Abcellera Biologics Inc. to Announce Full Year 2025 Financial Results
Reuters · 01/22 21:05
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Barchart · 01/22 15:05
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial
Simply Wall St · 01/22 11:42
Weekly Report: what happened at ABCL last week (0112-0116)?
Weekly Report · 01/19 09:09
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer?
Simply Wall St · 01/17 01:47
AbCellera Biologics Showcases Progress in Antibody Drug Development and Clinical Pipeline
Reuters · 01/14 22:04
BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
Reuters · 01/12 15:40
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
TipRanks · 01/12 14:36
BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug
Reuters · 01/12 14:11
AbCellera Doses First Participants In Phase 2 Portion Of Its Phase 1/2 Clinical Study For ABCL635 To Treat Moderate-To-Severe Vasomotor Symptoms Associated With Menopause
Benzinga · 01/12 14:10
AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms
Reuters · 01/12 14:01
ABCELLERA BIOLOGICS INC - ANTICIPATES TOP-LINE RESULTS IN Q3 2026
Reuters · 01/12 14:00
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.